Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.
Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system.
Major Conditions Strategy: MPs question government s cancer plans newstatesman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newstatesman.com Daily Mail and Mail on Sunday newspapers.
According to the study investigators, findings indicat that pneumococcal vaccination in older adults and other interventions should be considered for reducing the disease burden.
Investigators aim to find a substitution for incomplete Freund adjuvant, which is not suitable for use in humans but shows a strong response to antigen-specific systemic immune responses.